The FDA has turned down a pair of marketing applications for Regeneron’s CD20xCD3 bispecific antibody odronextamab to treat two common forms of non-Hodgkin lymphoma (NHL).
The decision throws a spanner into Regeneron’s plans for a strong launch of the drug in the NHL market, with a label that would be the broadest of any drug in the class.
